Baseline characteristics phase 2
| Tumor type, n (%) | CRC | Ovarian | SCCHN | GBM | RCC | All |
| n=21 | n=58 | n=24 | n=22 | n=14 | n=139 | |
| Age, years | ||||||
| Median | 53.0 | 64.0 | 65.5 | 58.0 | 63.5 | 62.0 |
| Range | 40.0, 72.0 | 40.0, 89.0 | 34.0, 77.0 | 35.0, 75.0 | 46.0, 78.0 | 34.0, 89.0 |
| Sex | ||||||
| Male | 11 (52.4) | 0 (0.0) | 17 (70.8) | 15 (68.2) | 11 (78.6) | 60 (43.2) |
| Female | 10 (47.6) | 58 (100) | 7 (29.2) | 7 (31.8) | 3 (21.4) | 79 (56.8) |
| ECOG PS | ||||||
| 0 | 10 (47.6) | 20 (34.5) | 9 (37.5) | 8 (36.4) | 9 (64.3) | 56 (40.3) |
| 1 | 11 (52.4) | 38 (65.6) | 15 62.5) | 14 (63.6) | 5 (35.7) | 83 (59.7) |
| Tumor stage | ||||||
| III | 0 (0.0) | 5 (8.6) | 1 (4.2) | N/A | 0 (0.0) | 6 (4.3) |
| IV | 21 (100) | 33 (56.9) | 23 (95.8) | N/A | 14 (100) | 111 (79.9) |
| No of prior regimens | ||||||
| 1–2 | 2 (9.6) | 17 (29.3) | 19 (79.2) | 20 (90.9) | 13 (92.9) | 71 (51.1) |
| 3–4 | 10 (47.6) | 20 (34.5) | 4 (16.7) | 2 (9.1) | 1 (7.1) | 37 (26.6) |
| ≥5 | 9 (42.9) | 21 (36.2) | 1 (4.2) | 0 (0.0) | 0 (0.0) | 31 (22.3) |
| Prior systemic treatment | ||||||
| Chemotherapy | 21 (100) | 58 (100) | 24 (100) | 22 (100) | 0 (0.0) | 125 (89.9) |
| Biologics | 21 (100) | 30 (51.7) | 13 (54.2) | 0 (0.0) | 0 (0.0) | 64 (46.0) |
| Kinase inhibitor | 6 (28.6) | 4 (6.9) | 0 (0.0) | 0 (0.0) | 14 (100) | 24 (17.3) |
| Immunotherapy* | 0 (0.0) | 0 (0.0) | 2 (8.3) | 3 (13.6) | 1 (7.1) | 8 (5.8) |
*Cytokines or toll-like receptor agonist.
CRC, colorectal cancer; ECOG, Eastern Cooperative Oncology Group; GBM, glioblastoma; N/A, not available; RCC, renal cell carcinoma; SCCHN, squamous cell carcinoma of the head and neck.